Mark McAllister, MD
Retina Specialist · Sacramento, CANPI 1669934394
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,053 of the $4,391 with a category attached, or 69.5%. Alcon accounts for 68.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $2,386 and has fallen 66.5% since, to $801 in 2025.
Across 53 payments — averaging $82.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Astellas Pharma US Inc$390
- AbbVie$215
- Glaukos Corporation$191
- Genentech USA, Inc.$180
- Regeneron Healthcare Solutions, Inc.$174
- plus $244 from 6 others
Across 7 payments — averaging $966.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$7K
What the payments were for
- Travel & lodging$1,23828%
- Food & beverage$3,05370%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 31 | $2,998 |
| Astellas Pharma US Inc | 5 | $390 |
| AbbVie(2 entities) | 2 | $215 |
| Glaukos Corporation | 2 | $191 |
| Genentech USA, Inc. | 2 | $180 |
| Regeneron Healthcare Solutions, Inc. | 3 | $174 |
| Apellis Pharmaceuticals, Inc. | 3 | $103 |
| Alimera Sciences, Inc. | 1 | $47 |
| Coherus Oncology, Inc. | 1 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Eyepoint US, Inc. | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$248
- Rocklatan$248
- SUSVIMO$150
- Hydrus Microstent$141
- IACCESS$140
- iStent inject W$140
- Constellation$133
- NGENUITY$131
- EYLEA HD$121
- AcrySof Toric Aspheric UV Absorbing IOL$120
- DURYSTA$115
How this compares
$4,391 in reported general payments places this provider in the 55th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 23 | $976 |
| Brimonidine Tartrate | 20 | $183 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $130 |
| Latanoprost | 19 | $108 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Sacramento
- Carlos Medina MendezSacramento$548K
- Margaret ChangSacramento$197K
- Glenn YiuSacramento$146K
- Joel PearlmanSacramento$33K
- David TelanderSacramento$18K
- Maryam GhiassiSacramento$10K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.